Takeda’s commitment to FIRAZYR

The patent for FIRAZYR® (icatibant injection) expires on July 15, 2019. After this date, generic versions of icatibant may become available. Brand name FIRAZYR will continue to be available.

Takeda remains committed to you and your patients with hereditary angioedema (HAE)

At Takeda, our ongoing commitment to FIRAZYR includes the following:

  • Continued manufacturing and availability of FIRAZYR
  • Product support services through OnePath® for your eligible FIRAZYR patients
  • Resources to help make patients aware of the patent expiration for FIRAZYR

Contact the Takeda representative in your area with questions you may have about treatment with FIRAZYR.

Support through OnePath

OnePath will continue to help support your enrolled patients by offering access to a dedicated Patient Support Manager (PSM).

Helping your patients who want to receive FIRAZYR

We are making resources available that offer information about how to help your patients who you decide should receive brand name FIRAZYR.

You can also contact the OnePath Patient Support Manager or Patient Access Manager in your area if you have questions about access to FIRAZYR.